New Alzheimer's drug lacks a 'net health benefit,' ICER says

The Institute for Clinical and Economic Review found lecanemab, Eisai and Biogen's recently approved Alzheimer's drug, failed to "demonstrate a net health benefit" when compared to supportive care for adults with early Alzheimer's disease. 

Lecanemab's list price is $26,500 per year, and the ICER said its health-benefit price benchmark is between $8,900 and $21,500 per year. Of the 15 panelists part of the decision, all said the current price shows a "low" long-term value, according to a report released April 17.

The FDA approved the drug in early January, but CMS refused to adjust its Aduhelm-era coverage plan, setting a more strained market for the treatment. 

In a phase 3 trial, the anti-amyloid drug slowed cognitive decline by 27 percent in a global study of 1,795 people with mild cognitive impairment or mild Alzheimer's disease. However, the ICER said the drug costs 19 percent to 66 percent higher than its benefit.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like